MedTrace Logo

DOMPE -MT Neurotrophic Keratitis

NCT06947850 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-04-27

No results posted yet for this study

Summary

TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis

Conditions

Interventions

DRUG

Cenegermin Ophthalmic Solution [Oxervate]

Oxervate (cenegermin-bkbj) is commonly used to treat neurotrophic keratitis

Sponsors & Collaborators

  • Toyos Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-21
Primary Completion
2025-09-25
Completion
2025-09-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06947850 on ClinicalTrials.gov